Suchergebnisse - "Hasebe, Chitomi"

PubPharm (69)

1

Effect of treatment periods on efficacy of glecaprevir and pibrentasvir in chronic hepatitis C : A nationwide, prospective, multicenter study

enthalten in: JGH open : an open access journal of gastroenterology and hepatology | 2024

von Morita, A. | Tamaki, N. | Kobashi, H. | +26

2

Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2014 to 2018 in Japan : A large-scale multicenter retrospective study

enthalten in: Hepatology research : the official journal of the Japan Society of Hepatology | 2023

von Fujii, H. | Suzuki, Y. | Sawada, K. | +31

3

Necessity for surveillance for hepatocellualr carcinoma in older patients with chronic hepatitis C who achieved sustained virological response

enthalten in: JGH open : an open access journal of gastroenterology and hepatology | 2023

von Ishido, S. | Tamaki, N. | Kurosaki, M. | +24

4

Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma : a multicenter study by the Japan Red Cross Liver Study Group

enthalten in: Investigational new drugs | 2023

von Takaki, S. | Kurosaki, M. | Mori, N. | +22

5

Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group

enthalten in: Investigational new drugs | 2023

von Takaki, S. | Kurosaki, M. | Mori, N. | +22

6

Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group

enthalten in: Investigational new drugs | 2023

von Takaki, S. | Kurosaki, M. | Mori, N. | +22

7

Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group

enthalten in: Investigational new drugs | 2023

von Takaki, S. | Kurosaki, M. | Mori, N. | +22

8

Usefulness of neutrophil-to-lymphocyte ratio in predicting progression and survival outcomes after atezolizumab-bevacizumab treatment for hepatocellular carcinoma

enthalten in: Hepatology research : the official journal of the Japan Society of Hepatology | 2023

von Ochi, H. | Kurosaki, M. | Joko, K. | +21

9

Usefulness of neutrophil‐to‐lymphocyte ratio in predicting progression and survival outcomes after atezolizumab–bevacizumab treatment for hepatocellular carcinoma

enthalten in: Hepatology Research | 2023

von Ochi, H. | Kurosaki, M. | Joko, K. | +21

10

Necessity for surveillance for hepatocellualr carcinoma in older patients with chronic hepatitis C who achieved sustained virological response

enthalten in: JGH Open | 2023

von Ishido, S. | Tamaki, N. | Kurosaki, M. | +24

1
2
3
4
5
6
7
Nächster »
[7]